EDSA Edesa Biotech Corp: מקדם חוב לטווח ארוך להון

Edesa Biotech, Inc. (EDSA) focuses on developing anti-systemic inflammation therapies for the treatment of skin and lungs. The development of antibodies to control immune responses promises the company long-term profits, while laboratory capacities are fully utilized for clinical trials. The long-term capital structure metric illustrates the market reaction, where 0.00 serves as the base parameter value, determining the balance between borrowed funds and expansion.

To minimize credit risks, it is essential for an investor to assess the issuer's debt load. This ratio is calculated as the quotient of long-term liabilities to total equity. Analyzing the ratio of loans exceeding one year to equity allows for the determination of the business's financial autonomy. Low values confirm the stability of the liability structure. For Edesa Biotech, Inc. (EDSA), this is critical when financing the development of drugs against ARDS and skin pathologies.